Edgewise Therapeutics, Inc. (EWTX)


+0.12 (+1.51%)
Symbol EWTX
Price $8.08
Beta 0.000
Volume Avg. 0.24M
Market Cap 400.572M
Shares () -
52 Week Range 5.405-24.3
1y Target Est -
DCF Unlevered EWTX DCF ->
DCF Levered EWTX LDCF ->
ROE -18.14% Sell
ROA -18.57% Sell
Operating Margin -
Debt / Equity 4.76% Neutral
P/E 2.64 Buy
P/B 1.54 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest EWTX news

Dr. Peter A. Thompson
NASDAQ Global Select

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.